Mechlorethamine
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Mechlorethamine: Relapsing-remitting multiple sclerosis
One-Sentence Summary
Mechlorethamine is a cytotoxic alkylating agent that is marketed in Canada as a single-ingredient product. The TxGNN model predicts it may be effective for relapsing-remitting multiple sclerosis, with a score of 0.9913. However, no clinical trials and no publications in the data compiled for this report support this prediction, so it rests on the model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Relapsing-remitting multiple sclerosis |
| TxGNN Prediction Score | 0.9913 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Mechlorethamine belongs to the nitrogen mustard alkylating agents, which damage DNA and kill rapidly dividing cells, including lymphocytes.
A plausible but speculative rationale is that cytotoxic alkylators and other immunosuppressants (for example cyclophosphamide and mitoxantrone) deplete autoreactive lymphocytes, which are thought to drive relapsing-remitting multiple sclerosis. This reasoning has not been tested for mechlorethamine in the compiled data.
There are also strong reasons for caution. Mechlorethamine is a vesicant and is associated with myelosuppression, gonadal toxicity and secondary malignancy. Many approved disease-modifying therapies already exist for this condition, so a favourable benefit-risk balance appears unlikely. The Canadian product is a topical gel with minimal systemic exposure, so it would not plausibly act on central nervous system disease.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02516764 | LEDAGA | Not specified | Not specified |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (nitrogen mustard alkylating agent) |
| Myelosuppression Risk | High for systemic exposure; the topical gel has minimal systemic exposure |
| Emetogenicity Classification | High with intravenous use; low with topical use |
| Monitoring Items | Complete blood count with differential, liver and renal function, uric acid; skin assessment for topical use |
| Handling Protection | Yes. It is a vesicant and must be handled according to cytotoxic drug handling regulations |
Safety Considerations
- Conditions of concern (contraindication relations from the data compiled for this report, not label text): thrombocytopenia, anemia, leukopenia, agranulocytosis, neutropenia (including congenital and idiopathic forms), blood coagulation disease, hyperuricemia and amyloidosis. These are consistent with the drug’s bone marrow toxicity.
- Drug Interactions: 100 interactions were found. Examples rated Major include deferiprone, samarium (153Sm) lexidronam, adalimumab and baricitinib. Examples rated Moderate include mercaptopurine, azathioprine, zidovudine, chloramphenicol, alemtuzumab, aldesleukin and anakinra. Live or inactivated vaccines (anthrax, tetanus toxoid) are also flagged as Moderate. Minor examples include levofloxacin and warfarin.
Please also refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a high model score. No trials or publications address mechlorethamine in relapsing-remitting multiple sclerosis, and the drug’s toxicity profile and the many established therapies make a favourable benefit-risk balance unlikely.
To proceed, the following is needed:
- Preclinical or mechanistic evidence that mechlorethamine acts on the pathology of multiple sclerosis
- Detailed mechanism-of-action data
- The Health Canada package insert warnings and contraindications
- A route and exposure assessment, since the marketed topical gel is unlikely to reach the central nervous system
- A benefit-risk comparison against currently approved disease-modifying therapies
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.